ALEC
Alector, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.46
−1.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 13.9M | 21.0M | 100.6M | 97.1M | 133.6M |
| Cost of Revenue | 63.9M | 9.7M | 185.9M | 8.8M | — |
| Gross Profit | (50.0M) | 11.4M | (85.4M) | 88.2M | 133.6M |
| Operating Expenses | |||||
| R&D Expense | 95.6M | 123.1M | 209.2M | 192.1M | 210.4M |
| SG&A Expense | 38.3M | 54.0M | 57.4M | 56.7M | 61.0M |
| General & Admin Expense | 38.3M | 54.0M | 57.4M | 56.7M | 61.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (57.2M) | (19.9M) | (207.0M) | (8.8M) | — |
| Total Operating Expenses | 76.8M | 157.2M | 59.6M | 240.0M | 271.5M |
| Cost and Expenses | 140.6M | 166.9M | 245.6M | 248.8M | 271.5M |
| Operating Income (EBIT) | (126.8M) | (145.8M) | (145.0M) | (151.7M) | (137.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 9.2M | 3.0M | 26.1M | 26.6M | 7.8M |
| Non-Operating Income (excl Interest) | (9.2M) | (3.0M) | (26.1M) | (26.6M) | (7.8M) |
| EBT (Pre-Tax Income) | (117.6M) | (142.8M) | (118.9M) | (125.2M) | (130.1M) |
| Income Tax Expense | 298.0K | 168.0K | 128.0K | 5.2M | 3.3M |
| Bottom Line | |||||
| Net Income | (117.9M) | (142.9M) | (119.0M) | (130.4M) | (133.3M) |
| Earnings from Cont. Ops | (117.9M) | (142.9M) | (119.0M) | (130.4M) | (133.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (117.9M) | (142.9M) | (119.0M) | (130.4M) | (133.3M) |
| Per Share | |||||
| Basic EPS | ($1.10) | ($1.39) | ($1.23) | ($1.56) | ($1.62) |
| Diluted EPS | ($1.10) | ($1.39) | ($1.23) | ($1.56) | ($1.62) |
| Revenue Per Share | $0.12 | $0.20 | $1.04 | $1.16 | $1.62 |
| Shares | |||||
| Basic Shares Outstanding | 111.2M | 103.0M | 96.6M | 83.7M | 82.5M |
| Diluted Shares Outstanding | 111.2M | 103.0M | 96.6M | 83.7M | 82.5M |
| Profitability Metrics | |||||
| EBITDA | (107.8M) | (133.1M) | (110.1M) | (116.3M) | (121.6M) |
| D&A | 9.7M | 9.7M | 8.8M | 8.8M | 8.5M |
| EBIT | (117.6M) | (142.8M) | (118.9M) | (125.2M) | (130.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026